Dengue type 2 virus (DV)-induced cytotoxic factor (CF) is capable of reproducing various pathological lesions in mice that are seen in human dengue. The present study was undertaken to investigate the protective effect ofactive immunization ofmice with CF. Mice were immunized with 5 ug of CF and prevention of CF-induced increase in capillary permeability and damage to the bloodbrain barrier were studied at weekly intervals, up to 48 weeks, by challenging with 3 pg of CF. Maximum protection against increase in capillary permeability and damage to the blood-brain barrier was observed in week 4 after immunization. A breakthrough in the protection occurred with higher doses of CF in a dose-dependent manner. Challenge with a lethal intracerebral (i.c.) dose of DV showed significantly prolonged mean survival time and delayed onset of symptoms of sickness in the immunized mice compared with the normal mice, but the titre of the virus in the brain was similar in the two groups. On i.p. challenge with the virus the protection against damage to the blood-brain barrier was 86 + 7% at week 4 and 17 + 4% at week 26 after immunization. Sera obtained from the immunized mice showed the presence of CF-specific antibodies by ELISA, Western blot, and by neutralization of the cytotoxic activity of CF in vitro. The present study describes successful prevention of a cytokine-induced pathology by specific active immunization.
INTRODUCTION
Cytokines act in a network of communication signals between different types of cells. Under normal conditions the blood concentration of cytokines is usually low, and they are quickly eliminated or rendered inactive. Under pathological conditions higher levels of different cytokines have been noted; however, their role in the pathogenesis ofdisease is convincing for some of them only. For example, the role of tumour necrosis factor (TNF) in cerebral malaria [1] [2] [3] , meningococcal septicaemia [4] and lethal infection of Escherichia coli in baboons [5] is known. Other cytokines which may produce pathological effects are IL-1 [6] , IL-6 [7] , IL-8 [8] and others [9] .
Dengue haemorrhagic fever/shock syndrome (DHF/DSS) is characterized by increased vascular permeability, thrombocytopenia, alterations in blood leucocytes and cerebral oedema. The pathogenesis of the disease is not known, nor is an effective vaccine available (reviewed in [10] ). During dengue type 2 virus (DV) infection of mice a cytokine, called cytotoxic factor (CF), is produced by T cells of the spleen. CF is a highly potent protein molecule of 43-45 kD with an isoelectric point of pH 6 5 that of other known cytokines and the dengue virus-specific proteins (Gen Data Base, compared at Distributed Information Centre, Indian Institute of Science, Bangalore), thus indicating that it is a unique cytokine. Oligonucleotide probes derived from this sequence show the presence of mRNA for CF in the spleen cells of DV-infected mice ([1 1]; unpublished data). CF killed mainly H-2A-negative macrophages, T helper (Th) cells and megakaryocytes of lymphoid cells from a variety of animal species, including mice, by increasing influx of Ca2+ in them. CF induces H-2A-positive macrophages to produce another cytotoxin (CF2). CF/CF2 are capable of producing a number of pathological lesions in mice, which include reversible increase in vascular permeability and damage to the blood-brain barrier due to release of histamine. In vitro treatment of human blood leucocytes with CF decreases the E-rosetting capacity of T cells and the functions ofmonocytes, which are similar to the changes described in cases of DHF/DSS [12] . It would thus appear that CF is capable of reproducing the pathological lesions of DHF in mice [13] [14] [15] [16] [17] [18] [19] [20] . The concept of pathogenesis-related proteins during viral infection of plants is well established [21] . It appears that CF is a pathogenesis-related protein, at least in mouse dengue infection. Efforts have been made to neutralize the adverse effects of the cytokines by passive immunization, for example by administration of antibodies against TNF [1] . The pathological effects produced by CF/CF2 could be prevented by passive administration of the specific antibody in mice [16, 17, 19] . In the present study, an effort was made to investigate whether a vaccine could be developed for dengue using CF as antigen. We describe here our limited success in this regard.
MATERIALS AND METHODS

Mice
The study was carried out on inbred Swiss albino mice aged [2] [3] months, obtained from the colony maintained in this Department.
Virus DV, strain P 23085, obtained from the National Institute of Virology, Pune, India, was used in the form of infected mouse brain suspension. The titre of the virus was estimated in the brain tissue of mice following intracerebral (i.c.) inoculation of DV as described [16, 22] . Briefly, serial 10-fold dilutions of the brain suspension were inoculated intracerebrally in groups of six mice each and the mortality was recorded. The virus titre was calculated by the method of Reed & Muench [23] Preparation of the cytotoxic factor CF was prepared from DV-infected moribund mouse spleen cells as described elsewhere [11] and its cytotoxic activity was assayed [24] . CF Assay of capillary permeability Measurement of leakage of plasma protein-bound Evans blue dye from the vascular compartment into the peritoneal cavity of the mouse was used to estimate the integrity of the capillary permeability, as described previously [17] . Briefly, mice were inoculated intravenously with 100 p1 of Evans blue dye solution, followed 5 min later with CF intraperitoneally. After 30 min mice were anaesthetized and the peritoneal cavity was washed with 5 ml PBS. The lavage fluid was collected, filtered through glasswool column and made up to final volume of 10 ml. The optical density at 590 nm was determined with a spectrophotometer. The protein content of the fluid was calculated as pg protein/ml. The results were expressed as PI, as described above.
The control mice were inoculated with NF. The per cent protection in immunized mice was calculated as described above. The mice at week 20 after immunization behaved like normal mice. The findings presented in Fig. 3 show the cumulative mortality rate in control and immunized mice. The curve has shifted significantly (P < 0-001) to the right with mice at 3, 4 and *0- Effect on blood-brain barrier. The effect of CF challenge on the blood-brain barrier was examined in a few groups of mice Presence of anti-CF antibodies in immunized mice Groups of mice immunized with CF were bled and the serum from individual mice was investigated for the presence of anti-CF antibodies at different periods. ELISA test. At 1 week after immunization 56% of sera had anti-CF antibody titres above the cut-off value in the ELISA. The seropositivity was 100% during the weeks 2-8, and then declined gradually to 21% at week 24 . At later periods none of the sera was positive (Fig. 5) . The mean antibody titres gradually increased during the post-immunization period, reaching peak values at week 4 and then declining. This correlated with the extent of protection shown in Fig. 1 .
ELISA
Neutralization of the activity of CF by sera of the immunized mice. CF kills normal mouse spleen cells in vitro in 1 h at 4 C [24] . The protective effect of the sera from immunized mice on the cytotoxicity of CF was therefore investigated. The ability of the sera from immunized mice to neutralize the cytotoxicity of CF gradually increased with the time after immunization till week 4, persisted up to week 8, and then declined. 
DISCUSSION
The significant finding of the present study is that active immunization by a cytokine (CF) protects mice against its adverse effects on subsequent challenge. The protection against the CF-induced increase in capillary permeability was complete at week 4 after immunization to a challenging dose of 3 yg/ mouse of CF. A breakthrough in the protection occurred with higher doses of CF in a dose-dependent manner. The sera obtained from these mice had CF-specific antibodies as shown by ELISA and Western blot tests (results not shown), and had the capacity to neutralize the cytotoxic activity of CF in vitro. All these effects were dependent on the period after immunization.
On i.c. inoculation, DV replicates in the brain of mice, and produces encephalitis followed by paralysis of limbs and death. The virus spreads all over the body and can be detected in different organs [27, 28] . DV lacks the ability to invade the central nervous sysetm (CNS) when inoculated by peripheral routes (reviewed in [29] ). Further, no apparent illness is produced by i.p. inoculation of DV in mice, but damage to the blood-brain barrier and increase in vascular permeability, mediated by CF, do occur [16, 17] . The onset of paralysis was delayed, mean survival time was significantly prolonged (P <0001) and the clinical symptoms, like arching of the back and ruffling of the fur, were mostly absent in CF-immunized mice compared with the normal mice by lethal i.c. challenge with DV. The virus titres in the brain tissue were similar in the two groups. Similar prolonged mean survival times after a lethal challenge with viruses have been reported in T cell-deficient mice, such as athymic nude (nu/nu) mice [27] or those treated with anti-thymocyte serum [30] . In DV-infected mice the brain is damaged by replication of the virus and by a DV-induced T cell cytokine, the CF [16] . It has been shown that paralysis and death of mice occur due to replication of DV in the neuron cells, while damage to the blood-brain barrier, resulting in cerebral oedema and associated symptoms, is caused both by the virus and CF [16, 29] . In the present study neither the virus titre nor the DVinduced paralysis and death could be prevented by CF immunization, but the latter was significantly delayed and the pathological lesions produced by challenging the mice with CF were prevented. On the other hand, in further experiments where the virus did not enter the brain (i.p. inoculation) the immunization provided specific protection (86 + 7%) against damage to the blood-brain barrier on challenging with DV.
Several successful attempts have been made to immunize passively animals with anti-cytokine antibodies to neutralize its adverse effects. Beutler et al. [31] protected mice from the lethal effects of endotoxin by passive immunization against TNF. Development of cerebral oedema, haemorrhage and leakage of protein across the blood-brain barrier in cerebral malaria are prevented by antibodies against TNF, and a MoAb to E. coli [6] . Specific antisera protect mice against CF/CF2-induced increase in capillary permeability and breakdown of the blood-brain barrier [16] [17] [18] [19] .
However, it may noted that not all antibodies against cytokines inhibit their function. Bendtzen et al. [32] have reviewed the role of autoantibodies to cytokines, and have suggested that anti-cytokine antibodies (neutralizing type) may produce 'cytokine deficiency', thus inhibiting their functions, while in some cases they (non-neutralizing type) contribute to a positive therapeutic response by better targeting to the appropriate cells.
This initial success with active immunization using a cytokine has raised several questions: (i) Playfair et al. [3] have discussed the role of 'anti-parasite' versus 'anti-disease' vaccine in relation to malaria. They have cited evidence to show that soluble antigens (toxins) released from Plasmodium falciparum have properties of bacterial lipopolysaccharides and induce over-production of TNF which is responsible for the disease. Therefore, they have proposed the possibility of an 'anti-toxic vaccine' that prevents the serious pathological complications of the disease [3] . CF is a unique cytokine induced by DV which is responsible for the production of most of the pathological lesions which could be prevented by passive immunization [16, 17, 20] , and also by active immunization as shown in the present study. Therefore, vaccine strategies directed at the cytokine (the primary cause) rather than the infective agents need serious consideration, especially when effective vaccines are not available for several agents.
